{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:15:34Z","timestamp":1790741734206,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.juro.2017.08.103","type":"journal-article","created":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T03:15:54Z","timestamp":1504322154000},"page":"459-464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Na\u00efve Prostate Cancer: 3-Year Open Label Followup Results"],"prefix":"10.1097","volume":"199","author":[{"given":"Bertrand","family":"Tombal","sequence":"first","affiliation":[{"name":"Cliniques universitaires Saint-Luc, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Borre","sequence":"additional","affiliation":[{"name":"Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Rathenborg","sequence":"additional","affiliation":[{"name":"Herlev Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Werbrouck","sequence":"additional","affiliation":[{"name":"AZ Groeninge Kortrijk, Kortrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Van Poppel","sequence":"additional","affiliation":[{"name":"Universitair ziekenhuis Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"Cologne University, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Iversen","sequence":"additional","affiliation":[{"name":"Rigshospitalet, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Braeckman","sequence":"additional","affiliation":[{"name":"Universitair ziekenhuis Brussels, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Heracek","sequence":"additional","affiliation":[{"name":"Univerzita Karlova v Praze, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Baron","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc., Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Krivoshik","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc., Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hirmand","sequence":"additional","affiliation":[{"name":"Medivation, Inc., San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2017.08.103_bib1","author":"Mottet"},{"key":"10.1016\/j.juro.2017.08.103_bib3","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.08.103_bib4","first-page":"S3","article-title":"Androgen deprivation therapy in the treatment of advanced prostate cancer","volume":"9","author":"Perlmutter","year":"2007","journal-title":"Rev Urol"},{"key":"10.1016\/j.juro.2017.08.103_bib5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12885-015-1843-3","article-title":"Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand","volume":"15","author":"Wang","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.juro.2017.08.103_bib6","doi-asserted-by":"crossref","first-page":"e0117344","DOI":"10.1371\/journal.pone.0117344","article-title":"Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"10","author":"Bosco","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.juro.2017.08.103_bib7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.08.103_bib8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000019634","article-title":"A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer","volume":"33","author":"Tyrrell","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.08.103_bib9","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0022-5347(05)67032-2","article-title":"Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup","volume":"164","author":"Iversen","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.08.103_bib10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2017.08.103_bib11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2017.08.103_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","article-title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","volume":"17","author":"Shore","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.juro.2017.08.103_bib13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.juro.2017.08.103_bib14","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","article-title":"Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial","volume":"34","author":"Penson","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.08.103_bib15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","article-title":"Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study","volume":"15","author":"Tombal","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.juro.2017.08.103_bib16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.eururo.2015.01.027","article-title":"Long-term efficacy and safety of enzalutamide monotherapy in hormone-naive prostate cancer: 1- and 2-year open-label follow-up results","volume":"68","author":"Tombal","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.08.103_bib17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2017.08.103_bib18","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.08.103_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.08.103_bib20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.08.103_bib21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2017.08.103_bib22","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1097\/01.ju.0000127738.94221.da","article-title":"Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer","volume":"171","author":"Sieber","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.08.103_bib23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2017.08.103_bib24","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","article-title":"Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition","volume":"22","author":"Smith","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717774228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717774228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2017.08.103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:04:45Z","timestamp":1651208685000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2017.08.103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1016\/j.juro.2017.08.103"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2017.08.103","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Na\u00efve Prostate Cancer: 3-Year Open Label Followup Results","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2017.08.103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}